Rates of lobar atrophy in asymptomatic MAPT mutation carriers
Abstract
The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau (MAPT) mutation carriers.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1016/j.trci.2019.05.010
Entities
People
- Adam L. Boxer
- Bradley F. Boeve
- Christina Dheel
- Clifford Jack
- Danielle Brushaber
- David S. Knopman
- David T. Jones
- Debra Gearhart
- Howie Rosen
- Jeremy Syrjanen
- Jonathan Graff‐radford
- Julie Fields
- Kejal Kantarci
- Leah Forsberg
- Lefftds Consortium
- Maria Lapid
- Matthew L Senjem
- Neill R. Graff‐radford
- Nirubol Tosakulwong
- Qing Chen
- Ralitza Gavrilova
- Rosa Rademakers
- Timothy G. Lesnick
- Walter K. Kremers
- Zbigniew K Wszolek
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Association for Frontotemporal Degeneration
- AstraZeneca
- Avid Radiopharmaceuticals
- Biogen
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Little Family Foundation
- Mayo Clinic
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- National Institutes of Health
- Novartis
- Sichuan University
- United States Department of Defense
- University of California, San Francisco
- University of Southern California